Gut Bacteria and Diet May Explain Why Obesity Sometimes Boosts Cancer Immunotherapy

One of the most puzzling findings in modern oncology has been the so-called obesity paradox: although obesity raises the risk of developing many cancers and is generally linked to worse outcomes, patients with a higher body mass index sometimes respond better to a widely used form of cancer immunotherapy. A new study from McGill University, published in Nature, offers a mechanistic explanation for this contradiction, and the answer appears to lie not in body weight itself but in the interplay between what we eat and the trillions of bacteria that inhabit the digestive tract. The work suggests that the relationship between diet and cancer treatment success is far more intricate than the simple advice to eat well and exercise, and it points toward new strategies for improving immunotherapy for patients who currently fail to benefit from it.

The treatment at the center of the research is immune checkpoint blockade, a class of drugs that releases the molecular brakes that tumors place on the immune system. Checkpoint inhibitors have transformed the prognosis for several cancers, including melanoma and lung cancer, yet a substantial proportion of patients derive little or no benefit. For years, researchers have tried to identify the factors that separate responders from non-responders, and among the most intriguing candidates has been the gut microbiome, the vast community of microbes that lives in the gastrointestinal tract and communicates constantly with the immune system. Diet, in turn, is one of the most powerful levers shaping the composition and activity of that microbial community.

Daniela Quail, Associate Professor in the Department of Physiology at McGill and Principal Investigator at the Rosalind & Morris Goodman Cancer Institute, co-led the investigation alongside McGill researcher Logan Walsh and CR-CHUM collaborators Bertrand Routy and Arielle Elkrief. The team set out to test how different diets influence responses to checkpoint inhibitors, using mice as a model system. Their experimental design was unusually broad: rather than examining a single dietary manipulation, the researchers compared twelve distinct diets, allowing them to disentangle the effects of specific nutritional patterns on both the microbiome and immunotherapy outcomes.

The results defied expectations. Some of the diets that would typically be labeled unhealthy or fattening, and that are associated with weight gain, actually improved the animals’ responses to immunotherapy. Even more striking, the benefit appeared after relatively short periods of exposure, indicating that the relevant mechanism does not require the long-term metabolic changes that come with chronic obesity. As Quail noted, the findings highlighted a benefit of some obesogenic diets, a result she described as surprising because it complicates the conventional message that healthy eating is uniformly the best prescription for every aspect of health.

According to Quail, there is a synergistic relationship between the bacteria that reside in the gastrointestinal tract and the food we eat. Even when the gut contains the right composition of bacteria, the foods consumed to nourish those populations can determine whether a patient responds to treatment. In other words, the microbiome is not merely a static list of species but a dynamic metabolic engine whose output depends on the fuel it receives. That output, the study suggests, can either support or undermine the immune activation that checkpoint inhibitors are designed to unleash against tumors.

This framing helps resolve the obesity paradox in a way that previous studies could not. If higher body mass index were simply a marker of better immunotherapy response, one might expect that any route to weight gain would confer an advantage. The McGill team’s data instead indicate that the link between obesity and immunotherapy efficacy may have less to do with body weight than previously thought, and more to do with how diet and gut bacteria synergize to influence the immune system. Two patients with identical BMI values could harbor very different microbial communities, shaped by very different eating patterns, and therefore respond very differently to the same drug.

The researchers are careful to emphasize what the findings do not mean. Nothing in the study suggests that people with cancer should adopt diets associated with weight gain, which carries well-established health risks including cardiovascular disease, diabetes, and worse outcomes for many cancers. The obesogenic diets in the mouse experiments improved immunotherapy responses through specific, identifiable biological pathways, and the goal now is to isolate those pathways. If the team can determine exactly which dietary components, and which microbial metabolites, drive the enhanced immune response, clinicians might eventually be able to reproduce the benefit without the harmful consequences of an obesogenic diet.

That translational ambition is what makes the study significant beyond its immediate findings. Immunotherapy response is notoriously difficult to predict, and interventions aimed at the microbiome, such as fecal transplants or probiotic supplements, have produced mixed results in clinical trials. The McGill work suggests a reason for those mixed results: supplying the right bacteria may not be enough if the diet fails to nourish them in the right way. A rational microbiome-directed nutritional intervention would need to account for both halves of the synergy, pairing microbial composition with the specific nutrients that prompt those microbes to produce immune-supporting compounds.

The study, titled Diet–microbiome synergy underlies obesity-associated immunotherapy efficacy, was led by McGill PhD graduate Lysanne Desharnais together with Quail and their colleagues, and was published in Nature. Funding came from the Canadian Institutes of Health Research, the Canadian Cancer Society, the Terry Fox Research Institute, and the Canada Foundation for Innovation, with additional support from philanthropic partners including La Vie en Rose and the Bachynski Family Foundation. The breadth of that support reflects the interdisciplinary nature of the work, which sits at the intersection of immunology, microbiology, nutrition science, and clinical oncology.

For patients and clinicians, the immediate takeaway is one of cautious optimism rather than actionable change. No dietary recommendation for cancer patients should change on the basis of a mouse study, however elegant, and the well-known dangers of obesity-promoting diets remain firmly in place. But the research opens a concrete research agenda: identify the microbial metabolites generated under specific dietary conditions, test whether they enhance checkpoint inhibitor efficacy, and develop targeted supplements or dietary components that deliver the benefit safely. If that program succeeds, the obesity paradox will have served its purpose, transforming from a confusing clinical observation into a roadmap for making one of cancer medicine’s most powerful tools work for many more patients.

Subject of Research: How diet and gut microbiome interactions influence responses to immune checkpoint inhibitor cancer immunotherapy

Article Title: Focusing on the ‘obesity paradox’ to improve cancer treatment success

Article References: Focusing on the ‘obesity paradox’ to improve cancer treatment success. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: obesity paradox, cancer immunotherapy, immune checkpoint inhibitors, gut microbiome, diet, McGill University, Nature, oncology, microbiome-directed nutrition, tumor immunology, Daniela Quail, cancer research